Aclaris therapeutics completes enrollment in phase 2b study of ati-1777 for mild to severe atopic dermatitis (ati-1777-ad-202)

- top-line data anticipated around year end wayne, pa., oct. 03, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ati-1777-ad-202, its phase 2b trial of its investigational topical “soft” janus kinase (jak) 1/3 inhibitor, ati-1777, in patients with mild to severe atopic dermatitis.
ACRS Ratings Summary
ACRS Quant Ranking